Physician profile
Juan Lewis
NPI 1033164165
$433.84
in general payments reported to CMS, 2019-2025
16 companies · $61.07 in 2025
The $61.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.70 · 2020: $25.73 · 2021: $26.42 · 2022: $139 · 2023: $47.88 · 2024: $66.70 · 2025: $61.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $81.94 | 2022 | |
| Abbott Laboratories | $49.17 | 2023-2025 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $46.06 | 2025 | Isturisa |
| Astrazeneca Pharmaceuticals Lp | $35.85 | 2019-2023 | Farxiga |
| Abbvie INC. | $35.53 | 2019-2021 | |
| Almatica Pharma LLC | $26.68 | 2022 | |
| Redhill Biopharma INC. | $24.20 | 2024 | Talicia |
| Esperion Therapeutics, INC. | $24.19 | 2024 | Nexletol |
| Pfizer INC. | $18.65 | 2023 | |
| Lifescan, INC. | $16.69 | 2022 | |
| Roche Diabetes Care, INC. | $14.03 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.76 | 2020 | |
| Lilly USA, LLC | $12.00 | 2021 | |
| Merck Sharp & Dohme LLC | $11.97 | 2020 | |
| Ironwood Pharmaceuticals, INC | $11.63 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.